Bio News
Switzerland-based Roche has signed an agreement with Hanmi Pharmaceutical to secure the rights to HM17321, an obesity treatment designed to preserve muscle. Roche will pay an upfront payment of $190 million (approximately 268 billion won) and provide up to an additional $2.3 billion (approximately 3.24 trillion won) based on development, regulatory approval and sales milestones. Hanmi Pharmaceutical will complete the ongoing phase 1 dosing study before transferring development to Roche. The drug is a urocortin 2 analog that promotes muscle growth and fat metabolism.
BIOBOOK TEAM
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
